Skip to main content
Erschienen in: Virchows Archiv 1/2007

01.07.2007 | Original Article

Ki-67 expression in primary breast carcinomas and their axillary lymph node metastases: clinical implications

verfasst von: Daehoon Park, Rolf Kåresen, Tove Noren, Torill Sauer

Erschienen in: Virchows Archiv | Ausgabe 1/2007

Einloggen, um Zugang zu erhalten

Abstract

Proliferative activity of tumour cells assessed by immunohistochemical Ki-67 expression is one of several prognostic indicators in breast cancer. The major objective of this study was to investigate the prognostic impact of Ki-67 proliferative activity in the axillary lymph node metastases and in the matched primary breast carcinoma from 194 patients. There was a statistically significant up-regulation of Ki-67 protein in the metastatic deposit compared to where the primary tumour was found (p = 0.001). A low Ki-67 index in both the primary and the metastatic tumours was a favorable prognostic factor. A high index in both primary and metastatic lesion and an up-regulation from a low index in the primary tumour to a high index in the metastatic deposit represented an unfavorable prognostic factor. Multivariate analysis showed that Ki-67 expression in the metastases was a superior independent prognostic factor of clinical outcomes compared to that in the primary tumours. Ki-67 expression in ≥10% of carcinoma cells in the primary tumours and ≥15% in the nodal metastases seems to be optimal cut-off levels. Ki-67 is of value as an independent prognostic factor in breast cancer.
Literatur
1.
Zurück zum Zitat Beenken SW, Bland KI (2002) Biomarkers for breast cancer. Minerva Chir 57:437–448PubMed Beenken SW, Bland KI (2002) Biomarkers for breast cancer. Minerva Chir 57:437–448PubMed
2.
Zurück zum Zitat Betta PG, Robutti F, Pilato FP, Spinoglio G, Bottero G (1989) Correlation of proliferative activity with pathological features in breast carcinoma. Eur J Gynaecol Oncol 10:433–437PubMed Betta PG, Robutti F, Pilato FP, Spinoglio G, Bottero G (1989) Correlation of proliferative activity with pathological features in breast carcinoma. Eur J Gynaecol Oncol 10:433–437PubMed
3.
Zurück zum Zitat Bouzubar N, Walker KJ, Griffiths K, Ellis IO, Elston CW, Robertson JF, Blamey RW, Nicholson RI (1989) Ki67 immunostaining in primary breast cancer: pathological and clinical associations. Br J Cancer 59:943–947PubMed Bouzubar N, Walker KJ, Griffiths K, Ellis IO, Elston CW, Robertson JF, Blamey RW, Nicholson RI (1989) Ki67 immunostaining in primary breast cancer: pathological and clinical associations. Br J Cancer 59:943–947PubMed
4.
Zurück zum Zitat Bundred NJ (2001) Prognostic and predictive factors in breast cancer. Cancer Treat Rev 27:137–142PubMedCrossRef Bundred NJ (2001) Prognostic and predictive factors in breast cancer. Cancer Treat Rev 27:137–142PubMedCrossRef
5.
Zurück zum Zitat Buxant F, Anaf V, Simon P, Fayt I, Noel JC (2002) Ki-67 immunostaining activity is higher in positive axillary lymph nodes than in the primary breast tumor. Breast Cancer Res Treat 75:1–3PubMedCrossRef Buxant F, Anaf V, Simon P, Fayt I, Noel JC (2002) Ki-67 immunostaining activity is higher in positive axillary lymph nodes than in the primary breast tumor. Breast Cancer Res Treat 75:1–3PubMedCrossRef
6.
Zurück zum Zitat Campani D, De-Negri F, Fabbri R, Martini L, Giani C, Squartini F, Sarnelli R (1991) Estrogen, progesterone receptors and proliferating activity evaluated by immunocytochemistry in breast cancer. Int J Biol Markers 6:144–150PubMed Campani D, De-Negri F, Fabbri R, Martini L, Giani C, Squartini F, Sarnelli R (1991) Estrogen, progesterone receptors and proliferating activity evaluated by immunocytochemistry in breast cancer. Int J Biol Markers 6:144–150PubMed
7.
Zurück zum Zitat Colozza M, Azambuja E, Cardoso F, Sotiriou C, Larsimont D, Piccart MJ (2005) Proliferative markers as prognostic and predictive tools in early breast cancer: where are we now? Ann Oncol 16:1723–1739PubMedCrossRef Colozza M, Azambuja E, Cardoso F, Sotiriou C, Larsimont D, Piccart MJ (2005) Proliferative markers as prognostic and predictive tools in early breast cancer: where are we now? Ann Oncol 16:1723–1739PubMedCrossRef
8.
Zurück zum Zitat Di-Stefano D, Mingazzini PL, Scucchi L, Donnetti M, Marinozzi V (1991) A comparative study of histopathology, hormone receptors, peanut lectin binding, Ki-67 immunostaining, and nucleolar organizer region-associated proteins in human breast cancer. Cancer 67:463–471PubMedCrossRef Di-Stefano D, Mingazzini PL, Scucchi L, Donnetti M, Marinozzi V (1991) A comparative study of histopathology, hormone receptors, peanut lectin binding, Ki-67 immunostaining, and nucleolar organizer region-associated proteins in human breast cancer. Cancer 67:463–471PubMedCrossRef
9.
Zurück zum Zitat Ding SL, Sheu LF, Yu JC, Yang TL, Chen B, Leu FJ, Shen CY (2004) Expression of estrogen receptor-alpha and Ki67 in relation to pathological and molecular features in early-onset infiltrating ductal carcinoma. J Biomed Sci 11:911–919PubMed Ding SL, Sheu LF, Yu JC, Yang TL, Chen B, Leu FJ, Shen CY (2004) Expression of estrogen receptor-alpha and Ki67 in relation to pathological and molecular features in early-onset infiltrating ductal carcinoma. J Biomed Sci 11:911–919PubMed
10.
Zurück zum Zitat Elston CW, Ellis IO (1991) Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 19:403–410PubMedCrossRef Elston CW, Ellis IO (1991) Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 19:403–410PubMedCrossRef
11.
Zurück zum Zitat Fitzgibbons PL, Page DL, Weaver D, Thor AD, Allred DC, Clark GM, Ruby SG, O’Malley F, Simpson JF, Connolly JL, Hayes DF, Edge SB, Lichter A, Schnitt SJ (2000) Prognostic factors in breast cancer. College of American Pathologists Consensus Statement 1999. Arch Pathol Lab Med 124:966–978PubMed Fitzgibbons PL, Page DL, Weaver D, Thor AD, Allred DC, Clark GM, Ruby SG, O’Malley F, Simpson JF, Connolly JL, Hayes DF, Edge SB, Lichter A, Schnitt SJ (2000) Prognostic factors in breast cancer. College of American Pathologists Consensus Statement 1999. Arch Pathol Lab Med 124:966–978PubMed
12.
Zurück zum Zitat Gerdes J, Lemke H, Baisch H, Wacker HH, Schwab U, Stein H (1984) Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67. J Immunol 133:1710–1715PubMed Gerdes J, Lemke H, Baisch H, Wacker HH, Schwab U, Stein H (1984) Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67. J Immunol 133:1710–1715PubMed
13.
Zurück zum Zitat Jalava P, Kuopio T, Juntti-Patinen L, Kotkansalo T, Kronqvist P, Collan Y (2006) Ki67 immunohistochemistry: a valuable marker in prognostication but with a risk of misclassification: proliferation subgroups formed based on Ki67 immunoreactivity and standardized mitotic index. Histopathology 48:674–682PubMedCrossRef Jalava P, Kuopio T, Juntti-Patinen L, Kotkansalo T, Kronqvist P, Collan Y (2006) Ki67 immunohistochemistry: a valuable marker in prognostication but with a risk of misclassification: proliferation subgroups formed based on Ki67 immunoreactivity and standardized mitotic index. Histopathology 48:674–682PubMedCrossRef
14.
Zurück zum Zitat Jansen RL, Hupperets PS, Arends JW, Joosten-Achjanie SR, Volovics A, Schouten HC, Hillen HF (1998) MIB-1 labelling index is an independent prognostic marker in primary breast cancer. Br J Cancer 78:460–465PubMed Jansen RL, Hupperets PS, Arends JW, Joosten-Achjanie SR, Volovics A, Schouten HC, Hillen HF (1998) MIB-1 labelling index is an independent prognostic marker in primary breast cancer. Br J Cancer 78:460–465PubMed
15.
Zurück zum Zitat Landis JR, Koch GG (1977) The measurement of observer agreement for categorical data. Biometrics 33:159–174PubMedCrossRef Landis JR, Koch GG (1977) The measurement of observer agreement for categorical data. Biometrics 33:159–174PubMedCrossRef
16.
Zurück zum Zitat Locker AP, Birrell K, Bell JA, Nicholson RI, Elston CW, Blamey RW, Ellis IO (1992) Ki67 immunoreactivity in breast carcinoma: relationships to prognostic variables and short term survival. Eur J Surg Oncol 18:224–229PubMed Locker AP, Birrell K, Bell JA, Nicholson RI, Elston CW, Blamey RW, Ellis IO (1992) Ki67 immunoreactivity in breast carcinoma: relationships to prognostic variables and short term survival. Eur J Surg Oncol 18:224–229PubMed
17.
Zurück zum Zitat Michels JJ, Marnay J, Delozier T, Denoux Y, Chasle J (2004) Proliferative activity in primary breast carcinomas is a salient prognostic factor. Cancer 100:455–464PubMedCrossRef Michels JJ, Marnay J, Delozier T, Denoux Y, Chasle J (2004) Proliferative activity in primary breast carcinomas is a salient prognostic factor. Cancer 100:455–464PubMedCrossRef
18.
Zurück zum Zitat Offersen BV, Sorensen FB, Knoop A, Overgaard J (2003) The prognostic relevance of estimates of proliferative activity in early breast cancer. Histopathology 43:573–582PubMedCrossRef Offersen BV, Sorensen FB, Knoop A, Overgaard J (2003) The prognostic relevance of estimates of proliferative activity in early breast cancer. Histopathology 43:573–582PubMedCrossRef
19.
Zurück zum Zitat Paradiso A, Tommasi S, Barletta A, Leone B, Lacava J, Vellejo C, Labriola A, Marzullo F, Altieri R, Schittulli F, De Lena M (1999) Metastatic site and p53 primary tumor expression in previously untreated stage IV breast cancer patients. Anticancer Res 19:4523–4528PubMed Paradiso A, Tommasi S, Barletta A, Leone B, Lacava J, Vellejo C, Labriola A, Marzullo F, Altieri R, Schittulli F, De Lena M (1999) Metastatic site and p53 primary tumor expression in previously untreated stage IV breast cancer patients. Anticancer Res 19:4523–4528PubMed
20.
Zurück zum Zitat Petit T, Wilt M, Velten M, Millon R, Rodier JF, Borel C, Mors R, Haegele P, Eber M, Ghnassia JP (2004) Comparative value of tumour grade, hormonal receptors, Ki-67, HER-2 and topoisomerase II alpha status as predictive markers in breast cancer patients treated with neoadjuvant anthracycline-based chemotherapy. Eur J Cancer 40:205–211PubMedCrossRef Petit T, Wilt M, Velten M, Millon R, Rodier JF, Borel C, Mors R, Haegele P, Eber M, Ghnassia JP (2004) Comparative value of tumour grade, hormonal receptors, Ki-67, HER-2 and topoisomerase II alpha status as predictive markers in breast cancer patients treated with neoadjuvant anthracycline-based chemotherapy. Eur J Cancer 40:205–211PubMedCrossRef
21.
Zurück zum Zitat Pinder SE, Wencyk P, Sibbering DM, Bell JA, Elston CW, Nicholson R, Robertson JF, Blamey RW, Ellis IO (1995) Assessment of the new proliferation marker MIB1 in breast carcinoma using image analysis: associations with other prognostic factors and survival. Br J Cancer 71:146–149PubMed Pinder SE, Wencyk P, Sibbering DM, Bell JA, Elston CW, Nicholson R, Robertson JF, Blamey RW, Ellis IO (1995) Assessment of the new proliferation marker MIB1 in breast carcinoma using image analysis: associations with other prognostic factors and survival. Br J Cancer 71:146–149PubMed
22.
Zurück zum Zitat Sahin AA, Ro J, Ro JY, Blick MB, el-Naggar AK, Ordonez NG, Fritsche HA, Smith TL, Hortobagyi GN, Ayala AG (1991) Ki-67 immunostaining in node-negative stage I/II breast carcinoma. Significant correlation with prognosis. Cancer 68:549–557PubMedCrossRef Sahin AA, Ro J, Ro JY, Blick MB, el-Naggar AK, Ordonez NG, Fritsche HA, Smith TL, Hortobagyi GN, Ayala AG (1991) Ki-67 immunostaining in node-negative stage I/II breast carcinoma. Significant correlation with prognosis. Cancer 68:549–557PubMedCrossRef
23.
Zurück zum Zitat Scholzen T, Gerdes J (2000) The Ki-67 protein: from the known and the unknown. J Cell Physiol 182:311–322PubMedCrossRef Scholzen T, Gerdes J (2000) The Ki-67 protein: from the known and the unknown. J Cell Physiol 182:311–322PubMedCrossRef
24.
Zurück zum Zitat Silvestrini R, Daidone MG, Luisi A, Boracchi P, Mezzetti M, Di Fronzo G, Andreola S, Salvadori B, Veronesi U (1995) Biologic and clinicopathologic factors as indicators of specific relapse types in node-negative breast cancer. J Clin Oncol 13:697–704PubMed Silvestrini R, Daidone MG, Luisi A, Boracchi P, Mezzetti M, Di Fronzo G, Andreola S, Salvadori B, Veronesi U (1995) Biologic and clinicopathologic factors as indicators of specific relapse types in node-negative breast cancer. J Clin Oncol 13:697–704PubMed
25.
Zurück zum Zitat Spyratos F, Ferrero-Pous M, Trassard M, Hacene K, Phillips E, Tubiana-Hulin M, Le Doussal V (2002) Correlation between MIB-1 and other proliferation markers: clinical implications of the MIB-1 cutoff value. Cancer 15:2151–2159CrossRef Spyratos F, Ferrero-Pous M, Trassard M, Hacene K, Phillips E, Tubiana-Hulin M, Le Doussal V (2002) Correlation between MIB-1 and other proliferation markers: clinical implications of the MIB-1 cutoff value. Cancer 15:2151–2159CrossRef
26.
Zurück zum Zitat Talley LI, Grizzle WE, Waterbor JW, Brown D, Weiss H, Frost AR (2002) Hormone receptors and proliferation in breast carcinomas of equivalent histologic grades in pre- and postmenopausal women. Int J Cancer 98:118–127PubMedCrossRef Talley LI, Grizzle WE, Waterbor JW, Brown D, Weiss H, Frost AR (2002) Hormone receptors and proliferation in breast carcinomas of equivalent histologic grades in pre- and postmenopausal women. Int J Cancer 98:118–127PubMedCrossRef
27.
Zurück zum Zitat Tan PH, Bay BH, Yip G, Selvarajan S, Tan P, Wu J, Lee CH, Li KB (2005) Immunohistochemical detection of Ki67 in breast cancer correlates with transcriptional regulation of genes related to apoptosis and cell death. Mod Pathol 18:374–381PubMedCrossRef Tan PH, Bay BH, Yip G, Selvarajan S, Tan P, Wu J, Lee CH, Li KB (2005) Immunohistochemical detection of Ki67 in breast cancer correlates with transcriptional regulation of genes related to apoptosis and cell death. Mod Pathol 18:374–381PubMedCrossRef
28.
Zurück zum Zitat Tavassoli FA, Devilee P (2003) Tumours of the breast. In: Tavassoli FA, Devilee P (eds) Pathology and genetics of tumours of the breast and female genital organs (World Health Organization Classification of Tumours series 5). IARC, Lyon, pp 9–112 Tavassoli FA, Devilee P (2003) Tumours of the breast. In: Tavassoli FA, Devilee P (eds) Pathology and genetics of tumours of the breast and female genital organs (World Health Organization Classification of Tumours series 5). IARC, Lyon, pp 9–112
29.
Zurück zum Zitat Trihia H, Murray S, Price K, Gelber RD, Golouh R, Goldhirsch A, Coates AS, Collins J, Castiglione-Gertsch M, Gusterson BA (2003) Ki-67 expression in breast carcinoma: its association with grading systems, clinical parameters, and other prognostic factors—a surrogate marker? Cancer 97:1321–1331PubMedCrossRef Trihia H, Murray S, Price K, Gelber RD, Golouh R, Goldhirsch A, Coates AS, Collins J, Castiglione-Gertsch M, Gusterson BA (2003) Ki-67 expression in breast carcinoma: its association with grading systems, clinical parameters, and other prognostic factors—a surrogate marker? Cancer 97:1321–1331PubMedCrossRef
30.
Zurück zum Zitat Veronese SM, Gambacorta M (1991) Detection of Ki-67 proliferation rate in breast cancer. Correlation with clinical and pathologic features. Am J Clin Pathol 95:30–34PubMed Veronese SM, Gambacorta M (1991) Detection of Ki-67 proliferation rate in breast cancer. Correlation with clinical and pathologic features. Am J Clin Pathol 95:30–34PubMed
31.
Zurück zum Zitat Wintzer HO, Zipfel I, Schulte-Monting J, Hellerich U, von Kleist S (1991) Ki-67 immunostaining in human breast tumors and its relationship to prognosis. Cancer 67:421–428PubMedCrossRef Wintzer HO, Zipfel I, Schulte-Monting J, Hellerich U, von Kleist S (1991) Ki-67 immunostaining in human breast tumors and its relationship to prognosis. Cancer 67:421–428PubMedCrossRef
32.
Zurück zum Zitat Wrba F, Chott A, Reiner A, Reiner G, Markis-Ritzinger E, Holzner JH (1989) Ki-67 immunoreactivity in breast carcinomas in relation to transferrin receptor expression, estrogen receptor status and morphological criteria. An immunohistochemical study. Oncology 46:255–259PubMedCrossRef Wrba F, Chott A, Reiner A, Reiner G, Markis-Ritzinger E, Holzner JH (1989) Ki-67 immunoreactivity in breast carcinomas in relation to transferrin receptor expression, estrogen receptor status and morphological criteria. An immunohistochemical study. Oncology 46:255–259PubMedCrossRef
33.
Zurück zum Zitat Yamashita H, Nishio M, Toyama T, Sugiura H, Zhang Z, Kobayashi S, Iwase H (2004) Coexistence of HER2 over-expression and p53 protein accumulation is a strong prognostic molecular marker in breast cancer. Breast Cancer Res 6:24–30CrossRef Yamashita H, Nishio M, Toyama T, Sugiura H, Zhang Z, Kobayashi S, Iwase H (2004) Coexistence of HER2 over-expression and p53 protein accumulation is a strong prognostic molecular marker in breast cancer. Breast Cancer Res 6:24–30CrossRef
Metadaten
Titel
Ki-67 expression in primary breast carcinomas and their axillary lymph node metastases: clinical implications
verfasst von
Daehoon Park
Rolf Kåresen
Tove Noren
Torill Sauer
Publikationsdatum
01.07.2007
Verlag
Springer-Verlag
Erschienen in
Virchows Archiv / Ausgabe 1/2007
Print ISSN: 0945-6317
Elektronische ISSN: 1432-2307
DOI
https://doi.org/10.1007/s00428-007-0435-2

Weitere Artikel der Ausgabe 1/2007

Virchows Archiv 1/2007 Zur Ausgabe

Neu im Fachgebiet Pathologie